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Actin-related protein 2/3 (Arp2/3) complex is a
seven-subunit assembly that nucleates branched
actin filaments. Small molecule inhibitors CK-666
and CK-869 bind to Arp2/3 complex and inhibit
nucleation, but their modes of action are unknown.
Here, we use biochemical and structural methods
to determine the mechanism of each inhibitor. Our
data indicate that CK-666 stabilizes the inactive state
of the complex, blocking movement of the Arp2 and
Arp3 subunits into the activated filament-like (short
pitch) conformation, while CK-869 binds to a seren-
dipitous pocket on Arp3 and allosterically destabi-
lizes the short pitch Arp3-Arp2 interface. These
results provide key insights into the relationship
between conformation and activity in Arp2/3 com-
plex and will be critical for interpreting the influence
of the inhibitors on actin filament networks in vivo.
INTRODUCTION
Small molecule inhibitors play important roles as drugs and as
research tools, and increasing the types of macromolecules
that can be targeted by small molecules is an important focus
of pharmacological and biochemical studies. While active sites
of enzymes are frequently targeted, proteins lacking a catalytic
site can also be inhibited using molecules that disrupt protein-
protein interfaces critical for function. Small molecules can also
be used to inhibit large molecular assemblies that serve asmulti-
functional molecular machines (Pommier and Marchand, 2012).
In such assemblies, small molecules can selectively block one of
multiple active sites, protein-protein interfaces, or conforma-
tional changes critical for discrete aspects of macromolecular
function. Therefore, small molecule inhibitors can become
powerful tools to dissect the mechanism of macromolecular as-
semblies in vitro and in vivo. However, realization of this potential
requires a precise determination of how the small molecules
inhibit function.
Actin-related protein 2/3 (Arp2/3) complex is a seven-subunit
macromolecular machine that regulates the actin cytoskeleton.
It catalyzes the kinetically slow process of actin filament nucle-
ation (Cooper et al., 1983; Sept and McCammon, 2001), aChemistry & Biology 20,reaction regulated in cells to allow precise spatial and temporal
control of the assembly of actin filament networks (Firat-Karalar
and Welch, 2011). Arp2/3 complex binds to the sides of pre-
existing (mother) actin filaments and nucleates a new (daughter)
filament in a complex reaction that requires interaction of Arp2/3
complex with filaments, actin monomers, ATP, and activating
proteins called nucleation promoting factors (NPFs) (Goley and
Welch, 2006; Pollard, 2007; Figure 1A). WASp/Scar family pro-
teins, the best characterized NPFs, have a conserved region
called VCA. The CA motif of VCA binds Arp2/3 complex and
the V region binds actin monomers, tethering them to the com-
plex (Boczkowska et al., 2008; Marchand et al., 2001; Miki and
Takenawa, 1998). High-resolution X-ray crystal structures
show that, in the absence of NPFs, Arp2 and Arp3, the two
actin-related subunits in the complex, are splayed apart (Nolen
and Pollard, 2007; Robinson et al., 2001). Electron microscopy
reconstructions show that, upon activation, Arp2 moves 25 A˚
to form a dimer with Arp3 that mimics a short pitch actin dimer
within a filament, thereby providing a template for nucleation of
a new filament (Rouiller et al., 2008). How the activating factors
initiate short pitch conformation is not known, and whether small
molecules could be exploited to block this large conformational
change is not clear.
Previously, two distinct classes of small molecule Arp2/3 com-
plex inhibitors were discovered, CK-636 and CK-548, which
block nucleation of actin filaments by Arp2/3 complex in vitro
(Nolen et al., 2009). Treatment of cultured cells with these inhib-
itors blocks formation of actin structures known to require
Arp2/3 complex, including Listeria actin comet tails, podo-
somes, and yeast endocytic actin patches (Nolen et al., 2009;
Rizvi et al., 2009). Because they provide a simple, fast-acting,
and reversible method of inhibition, these compounds can be
powerful tools to probe the role of Arp2/3 complex in other
actin-remodeling processes. Crystal structures of CK-636 and
CK-548 bound to Arp2/3 complex provided preliminary clues
as to how they might function, but the molecular mechanism of
inhibition has not been determined.
Here, we use a combination of biochemical and biophysical
methods to determine the mechanisms of CK-666 and
CK-869, more potent versions of parent compounds CK-636
and CK-548. Despite their distinct binding sites, our data sug-
gest that both CK-666 and CK-869 inhibit nucleation by blocking
the movement of Arp2 into the short pitch conformation.
Remarkably, conformational trapping by each inhibitor is
accomplished by a different mechanism. CK-666 functions as
a classical allosteric effector, stabilizing the inactive state of701–712, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 701
Figure 1. CK-666 and CK-869 Bind to Different Sites on Arp2/3 Complex
(A) Overview of branching nucleation reaction showing proposed conformational change of Arp2 and Arp3 into the activated short pitch conformation.
(B) Structures of CK-666 and CK-869. Previously reported half maximal inhibitory concentration (IC50) values are indicated (Nolen et al., 2009).
(C) Overall bindingmode of CK-666 from a previously reported 2.5 A˚ X-ray crystal structure of CK-666 bound toBos taurus Arp2/3 complex (3UKR) (Baggett et al.,
2012). CK-666 (marked with arrow) binds at the interface of Arp3 (orange) and Arp2 (red). The other subunits of the complex are ARPC1–ARPC5 and are colored
green, cyan, magenta, blue, and yellow, respectively. CK-666 binding does not change the position of the subunits compared to inhibitor-free structures, but
appears to stabilize the splayed (inactive) conformation of the Arp2 and Arp3 subunits.
(D) Overall binding mode of CK-869 from the 2.75 A˚ X-ray crystal structure reported here. CK-869 (marked with arrow) binds to a hydrophobic pocket in Arp3
(orange). Color scheme is identical to (C).
(E) Close up of the binding pocket of CK-869. The binding site for CK-869 (gray) is identical to the site for CK-548 (magenta) and is exposed when the sensor loop
(arrow) flips into an open conformation.
See also Figure S1 and Table S1.
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Mechanism of Arp2/3 Complex Inhibitorsthe complex, while CK-869 appears to directly disrupt key pro-
tein-protein interfaces in the short pitch Arp2-Arp3 dimer to
destabilize the active state. By measuring the influence of the
inhibitors on interactions of the complex with NPFs, ATP, actin
monomers, and filaments, we provide insight into the relation-
ship between conformation and activation and a basis for under-
standing the effects of the inhibitors on branched actin networks
in vivo. These results support the feasibility of using small mole-
cules to both allosterically disrupt protein-protein interfaces and
to lock multiprotein complexes in inactive conformations by
targeting and stabilizing subunit interfaces.
RESULTS
Crystal Structure of CK-869 Bound to Arp2/3 Complex
CK-666 and CK-869 are commercially available compounds
derived from CK-636 and CK-548, respectively (Nolen et al.,
2009; Figure 1B). The recently reported crystal structure of
CK-666 bound to Arp2/3 complex showed that, like CK-636, it
binds to a pocket at the interface of Arp2 and Arp3, suggesting702 Chemistry & Biology 20, 701–712, May 23, 2013 ª2013 Elsevierboth inhibitors may block formation of the Arp2-Arp3 short pitch
dimer (Baggett et al., 2012; Figure 1C). While chemically similar
to its parent compound, it is not known if CK-869 occupies the
same binding pocket as CK-548. Therefore, we solved the
crystal structure of CK-869 bound toBos taurus (Bt) Arp2/3 com-
plex. A 2.75 A˚ resolution crystal structure showed that CK-869,
like CK-548, binds to a hydrophobic cleft in subdomain 1 of
Arp3, making a single hydrogen bond with the amide group
of Asn118 (Figures 1D, 1E, and Figure S1 available online;
Table S1). As with CK-548, binding of CK-869 locks the sensor
loop into an open position. Similarity between this structure
and the CK-548-bound structure indicates that CK-548 and
CK-869 use a common mechanism of inhibition.
CK-869 Causes Structural Changes in ATP-Bound Arp3
that May Contribute to Complex Inactivation
Arp2/3 complex requires ATP to nucleate actin filaments (Dayel
et al., 2001), and mutations in the nucleotide binding pockets
(NBP) of Arp2 or Arp3 cause defects in nucleation (Goley et al.,
2004; Martin et al., 2005) and branched network turnoverLtd All rights reserved
Figure 2. CK-869 Influences ATP-Induced Conformational Changes in Arp3
(A) ε-ATP binding assays in whichBtArp2/3 complex (0.4 mM) and 200 mMof either CK-666 or CK-869was titrated with ε-ATP and the fluorescence at 413 nmwas
measured.
(B) Binding of CK-869 does not block ATP-induced closure of the nucleotide cleft. Distances across nucleotide cleft as described in (D). Asterisks indicate
structures reported in this paper.
(C) Difference electron density maps calculated without phase contributions from ATP, Ca2+ (red sphere), or CK-869 contoured at 3.0 s show strong density for
both ATP and CK-869 bound to Arp3 subunit.
(D) Stereoview of Ca trace of Arp3 from the CK-869/ATP structure (red) with overlaid Arp3 from the apoenzyme CK-869 structure (cyan). CK-869 is shown
in stick representation with green carbons and ATP with yellow carbons. The black dotted line indicates the B1 distance (Thr14 CA to Gly173 CA), and
the blue dotted line indicates the C distance (Gly67 CA–Glu202 CA). P1, P1 phosphate binding loop; P2, P2 phosphate binding loop; 7/C, b7/aC loop;
S, sensor loop.
(E) Conformational changes caused by binding of CK-869 to the ATP-bound complex. Close-up stereo view of Arp3 from ATP bound inhibitor-free complex (PDB
ID Code 2P9K, purple sticks) overlaid onto Arp3 from the CK-869/ATP structure (blue sticks, ATP in yellow lines). Positive 3.0 s (green) and negative 3.5 s (red)
electron density from a differencemapwere calculated bymodeling the sensor loop and b7/aC loop from the CK-869/ATP structure in the conformation observed
in the 2P9K structure. CK-869 is labeled and rendered as gray sticks.
See also Figure S2 and Table S1.
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Mechanism of Arp2/3 Complex Inhibitors(Ingerman et al., 2013). Because neither inhibitor binds to the
NBP of Arp3 or Arp2, we ruled out direct competition with ATP
as an inhibition mechanism. However, the sensor loop in actin
and actin-related proteins is allosterically linked to the nucleotide
binding pocket (Nolen and Pollard, 2007; Otterbein et al., 2001),
so we reasoned that the sensor loop flip caused by CK-869
might influence ATP binding to Arp3. Therefore, we measured
the affinity of 1-N6-etheno-ATP (ε-ATP) to BtArp2/3 complex in
the presence and absence of inhibitors (Figure 2A). Previous ex-
periments showed that the signal of this assay is predominantly
due to binding of ε-ATP to Arp3 (Le Clainche et al., 2001; Martin
et al., 2005). ε-ATP boundwith a KD = 3.0 ± 0.4 mM in the absence
of inhibitor, and the KD did not change significantly in the pres-
ence of saturating CK-666 or CK-869, indicating that neither
compound inactivates Arp2/3 complex by blocking ATP binding
to Arp3. To determine if CK-869 influences ATP-induced confor-
mational changes, we solved the 2.5 A˚ cocrystal structure ofChemistry & Biology 20,Arp2/3 with bound ATP and CK-869. Importantly, CK-869 does
not prevent the cleft of Arp3 from closing, a conformational
change observed in other ATP-bound Arp2/3 complex struc-
tures and thought to be required for activation of the complex
(Goley et al., 2004; Nolen and Pollard, 2007; Rouiller et al.,
2008; Figures 2B–2D). However, binding of CK-869 to ATP-
loaded Arp3 caused several significant structural changes. First,
Pro115 and Pro116 in the loop between b7 and aC move1.5 A˚
toward the space previously occupied by the sensor loop (Fig-
ures 2E and S2). This movement causes Gln144, a conserved
residue in the nucleotide cleft, to adopt a position in which it
directly contacts the calcium in the nucleotide cleft, as opposed
to making a water-mediated contact, as observed in other ATP-
bound actin and Arp2/3 complex structures (Figure S2; Nolen
et al., 2004; Nolen and Pollard, 2007). These changes do not
occur in the CK-869-bound structure without ATP and may be
critical for inhibition by CK-869, as discussed below.701–712, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 703
Figure 3. Neither Inhibitor Significantly In-
fluences NPF Binding or Interactions with
Actin
(A) Hypothetical model of two CAs binding to Arp2/
3 complex in the inactive conformation (PDB ID
code 1K8K). Yellow stars indicate relative position
of T464C-B4M label in crosslinking assays.
(B) Photoactivatable crosslinking assay in which
BtArp2/3 complex (2.5 mM) and 8 mM N-WASP-
VCA-T464C-B4M (B4M-VCA) were crosslinked in
the presence of 200 mM CK-666, 200 mM CK-869,
80 mM cortactin-NTA (NTA), or 20 mM Crn1-UCC
(UCC). Double and single asterisks indicate
Arp3-VCA and Arp2-VCA crosslinked adducts,
respectively.
(C) Binding isotherm showing fluorescence
anisotropy of 100 nM Alexa-546-cortactin-NTA
titratedwith BtArp2/3 complex. Addition of 200 mM
CK-666 or 150 mM CK-869 did not affect the
binding affinity.
(D) Plot of maximum polymerization rate of 3 mM
15% pyrene-labeled actin with 20 nM BtArp2/3
complex versus N-WASP-VCA concentration in
the presence and absence of 200 mM inhibitors.
(E) Copelleting assay in which BtArp2/3 complex
was copelleted with 0–20 mM actin filaments and
DMSO or 200 mM CK-666 or CK-869.
(F) Plot of initial polymerization rate versus con-
centration of BtArp2/3 complex for a reaction
containing 20 nM gelsolin-capped actin filament
seeds, 2 mM 15% pyrene-labeled actin, and
DMSO or 200 mM inhibitor.
(G) TIRF debranching reactions in which Oregon
green-labeled actin was polymerized in the pres-
ence of 20 nM BtArp2/3 complex and 100 nM
GST-VCA for 6 min before flushing the chamber
with buffer (t = 0) containing either DMSO or
200 mM of inhibitor. Red arrowheads indicate de-
branching events. Yellow arrowheads indicate
stable branches.
(H) Quantification of debranching for DMSO and
inhibitor-containing reactions. Fraction of surviv-
ing branches was calculated from at least two
separate movies, with n = 47, 33, and 20 for the
DMSO, CK-666, and CK-869 conditions, respec-
tively.
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Mechanism of Arp2/3 Complex InhibitorsNeither Inhibitor Blocks the Low- or High-Affinity NPF
Binding Sites on the Complex
Wenext investigated the effect of the inhibitors on activator bind-
ing. Chemical crosslinking and analytical ultracentrifugation ex-
periments demonstrated that Arp2/3 complex binds to two
VCA molecules (Liu et al., 2011; Padrick et al., 2011). Isothermal
titration calorimetrymeasurements showed that VCA bindsmore
tightly to one of the two sites, consistent with a recent observa-
tion that only a 1:1 and not a 2:1 VCA:Arp2/3 assembly can be
isolated by gel filtration (Gaucher et al., 2012; Ti et al., 2011).
Initial characterization of the inhibitors showed that neither com-
pound significantly affects binding of monomeric N-WASp-VCA
to the high affinity NPF site, hypothesized to be on Arp2 and
ARPC1 (Figure 3A; Nolen et al., 2009; Padrick et al., 2011;
Ti et al., 2011). The second NPF site binds VCA 100-fold more
weakly and is hypothesized to be on Arp3 (Ti et al., 2011). Cross-
linking, X-ray crystallography, and molecular modeling suggest
the second NPF site is on the ‘‘back side’’ of Arp3 relative to704 Chemistry & Biology 20, 701–712, May 23, 2013 ª2013 Elsevierthe mother filament binding face (Padrick et al., 2011; Ti et al.,
2011; Figure 3A), although density from recent single particle-
averaged electron microscopy structures suggest VCA binds
to the pointed ends of Arp3 and Arp2 (Xu et al., 2011). Both
NPF binding sites are critical for activation of the complex (Ti
et al., 2011), but it is not known if the inhibitors affect interactions
of VCA with the low-affinity site. Therefore, we used a chemical
crosslinking assay to test the effect of the inhibitors on VCA bind-
ing at each site. N-WASp-VCA labeled with benzophenone-4-
maleimide (B4M) at position 464 (N-terminal to its C region)
forms a UV-induced covalent crosslink with Arp2 or Arp3 sub-
units, resulting in the appearance of two higher molecular weight
bands (Figure 3B). Addition of 200 mMCK-869 or CK-666 did not
significantly influence crosslinking to Arp2 or Arp3, suggesting
neither inhibitor functions by blocking VCA from binding to either
site. In contrast, addition of cortactin or Crn1, proteins that
compete with VCA at only the Arp3 or Arp2 site, respectively
(Liu et al., 2011; Weaver et al., 2002), significantly reducedLtd All rights reserved
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Mechanism of Arp2/3 Complex Inhibitorscrosslinking at their expected sites, demonstrating the sensitivity
of the assay. To quantitatively probe the binding to Arp3, we also
tested the effect of the inhibitors on the affinity of the N-terminal
acidic region (NTA) of cortactin in a fluorescence anisotropy
binding assay. Alexa-546-labeled NTA bound to the complex
with a KD of 0.98 ± 0.09 mM (Figure 3C). Neither CK-666 nor
CK-869 had a significant effect on the binding of Alexa-546-
NTA (KD = 1.2 ± 0.1 and 0.8 ± 0.1, respectively), however the
anisotropy saturates at a lower value in the presence of
CK-869, indicating the complex could adopt a different confor-
mation. Together, these data show that neither inhibitor has a
significant influence at either NPF site and that neither inhibitor
functions by blocking activator binding. Actin polymerization as-
says support this conclusion, since high concentrations of
VCA could not overcome inhibition by CK-666 and CK-869
(Figure 3D).
Inhibitors Do Not Influence Interactions with Sides or
Ends of Filaments or Disassemble Preformed Branches
Branching nucleation requires binding of the complex to the
sides of filaments (Achard et al., 2010; Goley et al., 2010; Mache-
sky et al., 1999), so we measured the influence of the inhibitors
on copelleting of the complex with preformed actin filaments.
BtArp2/3 complex bound to actin filaments with a KD = 0.9 ±
0.3 mM (Figure 3E). CK-666 and CK-869 each increased the
KD to 2 ± 1 mM, which is within the range of affinities measured
for uninhibited Arp2/3 complex from a range of species (Beltzner
and Pollard, 2008; Goley et al., 2010). Therefore, defects in actin
filament side binding cannot account for inhibition.
Arp2/3 complex also binds to the pointed ends of filaments,
and binding has been hypothesized to require adoption of the
short pitch dimer (Dayel and Mullins, 2004; LeClaire et al.,
2008; Rouiller et al., 2008). We measured pointed end capping
by titrating gelsolin-capped actin filaments with increasing con-
centrations of the complex and measuring polymerization from
free pointed ends. The apparent KD of Arp2/3 complex was
1.3 ± 0.2 mM without inhibitors and 0.6 ± 0.1 mM and 0.5 ±
0.05 mM in the presence of 200 mMCK-666 and CK-869, respec-
tively (Figure 3F). Therefore, the inhibitors do not block pointed
end binding. To determine if the inhibitors influence interactions
of the complex with actin filaments in the context of a branch
junction, we used total internal reflection fluorescence (TIRF)
microscopy to monitor branch dissociation in the presence
and absence of the inhibitors. Branches were formed in the
absence of inhibitor then washed with a buffer containing inhib-
itor or DMSO as a control. Time-lapse movies show that neither
inhibitor increased the rate of branch dissociation over the time-
scale measured (Figures 3G and 3H). This suggests that neither
inhibitor actively disassembles branches.
CK-869 and CK-666 Block a Conformational Change
Caused by VCA-Recruited Actin Monomers Binding
to Arp2/3 Complex
Because neither inhibitor affected the interaction of Arp2/3 com-
plex with actin filaments, NPFs, or ATP, we next asked if the in-
hibitors influence actin monomer recruitment. Padrick et al.
(2011) recently used sedimentation velocity analytical ultracen-
trifugation (AUC) to demonstrate two VCA peptides, each with
an actin monomer bound, can simultaneously bind to Arp2/3Chemistry & Biology 20,complex to form a stable 2:2:1 VCA:actin:Arp2/3 complex.
We repeated this experiment using glutathione S-transferase
(GST)-dimerized VCA and showed that the sedimentation coeffi-
cient distribution profiles of a mixture of BtArp2/3 complex with
excess GST-VCA and latrunculin B-bound actin yielded peaks
at 5.8 S and 11.9 S. The experimentally determined molec-
ular weights of these peaks are consistent with a 2:2 GST-
VCA2:actin2 complex and a 2:2:1 actin2:GST-VCA2:Arp2/3
complex (Figures 4A and 4B). This demonstrates that GST-
VCA can simultaneously recruit two actin monomers to the com-
plex. We found that saturating concentrations of inhibitors
caused significant differences in sedimentation of the 2:2:1
assembly, with the peak shifting from 11.9 S to 11.4 S in the pres-
ence of CK-666 or CK-869 (Figures 4C–4F). Subsaturating
concentrations of each inhibitor resulted in broader peaks with
intermediate S values, indicating rapid conversion between
fast and slower sedimenting species (Figure 4C). Neither inhibi-
tor influenced the sedimentation profiles of Arp2/3 complex
alone, and both caused only small changes in the S values of
Arp2/3 complex with GST-VCA bound (Figures 4E and 4F).
The decreased sedimentation coefficient of the fast pelleting
species could be due to dissociation of components of the
2:2:1 assembly or a large conformational change caused by
the inhibitors. The reduction in S is not large enough to be consis-
tent with dissociation of either the entire GST-VCA2:actin2 heter-
otetramer or two actin monomers from the assembly, so we
reasoned that the inhibitors might cause dissociation of a single
actin monomer. To test this directly, we repeated the sedimenta-
tion velocity experiments using Oregon green-labeled actin to
track its sedimentation. If the inhibitors cause one actin mono-
mer to dissociate, the integrated area of the rapidly sedimenting
peak will decrease by one half. Instead, we observed that area of
the peak does not change in the presence of the inhibitors (Fig-
ure 4G). In addition, the frictional coefficient ratios of the 2:2:1
assemblies increased from 1.6 to 2.1 or 2.0 in the presence of
CK-666 or CK-869, respectively, indicating the inhibitor-bound
assembly adopts a less spherical conformation. Using the fric-
tional coefficients and the S values, we calculated the experi-
mental mass of the assemblies in the presence of the inhibitors
and found that they were also consistent with a 2:2:1 assembly
(Figure 4C). These observations indicate that inhibitors do not
cause actin monomers to dissociate from the 2:2:1 assembly
but instead cause a large conformational change that slows its
sedimentation.
Developing a Biochemical Assay to Directly Probe for
the Short Pitch Conformation
Our AUC data suggest that GST-VCA and actin monomers favor
a conformation of the complex that is blocked by the inhibitors.
While no high-resolution structures of the 2:2:1 assembly are
available, low resolution electron microscopy (EM) reconstruc-
tions of Arp2/3 complex with bound NPFs suggest that binding
of N-WASp alone stimulates formation of the short pitch Arp2-
Arp3 dimer (Xu et al., 2011). Therefore, we hypothesized that
the 2:2:1 assembly may adopt the short pitch conformation in
the absence of inhibitors and that this conformation is blocked
when inhibitors are bound. To test this hypothesis, we developed
a biochemical assay to directly detect the splayed (inactive) to
short pitch (filament-like) structural change. We engineered701–712, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 705
Figure 4. CK-666 and CK-869 Significantly Decrease the Sedimentation Rate of the GST-VCA2:actin2:Arp2/3 Complex in Sedimentation
Velocity Analytical Ultracentrifugation Experiments
(A) Sedimentation coefficient distribution for three sedimentation velocity runs containing 1 mM BtArp2/3 complex with or without 10 mM GST-VCA or 10 mM
GST-VCA plus 10 mM actin with 20 mM latrunculin B.
(B) Tabulation of sedimentation coefficients andmolecular weights for peaks observed in experiments in (A). exp, experimentally calculated; seq, calculated from
sequence.
(C) Sedimentation coefficient distribution of 1 mM BtArp2/3 complex with 10 mM GST-VCA, 10 mM actin, and 20 mM latrunculin in the presence or absence of
CK-666 or CK-869.
(D) Plot of sedimentation coefficient versus inhibitor concentration for peaks shown in (C) for a range of concentrations of CK-666 or CK-869.
(E and F) Sedimentation coefficient distribution of 1 mMBtArp2/3 complex alone (E) or with 10mMGST-VCA (F) in the presence or absence of CK-666 or CK-869.
(G) Sedimentation coefficient distributions for three sedimentation velocity runs monitored by absorbance at 491 nm containing 1 mM BtArp2/3 complex, 10 mM
GST-VCA, 10 mM 70% labeled Oregon Green-actin, 20 mM latrunculin B with or without 150 mM CK-666 or CK-869. Integrated peak areas averaged from three
separate runs are reported, along with the ratio of the fast sedimenting species compared to the total.
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Mechanism of Arp2/3 Complex Inhibitorscysteines in budding yeast Arp2/3 complex to create a crosslink-
ing probe sensitive to the relative position of Arp2 and Arp3. We
created two mutant complexes, Arp-021 and Arp-024, in which
cysteine pairs on Arp2 and Arp3 are predicted to bewithin cross-
linking distance in the short pitch Arp2-Arp3 dimer but not in the
splayed conformation (Figure 5A; Robinson et al., 2001; Rouiller
et al., 2008). While we observed some variability in preparations,
Arp-021 showed similar activity to the wild-type complex in
pyrene actin polymerization assays (Figures 5B and 5C). In con-
trast, Arp-024 consistently showed increased activity compared
to wild-type. Both mutant complexes were inhibited by CK-666,
though inhibition was weaker than in wild-type complex (Fig-
ure 5D). We are currently dissecting the molecular basis for the
differences in activity and in susceptibility to CK-666. We note
that, because both complexes are active, stimulated by NPF
(Figure 5C), and inhibited by CK-666, they can be used to probe
for inhibition of NPF-induced activating conformational change
by the inhibitor.
In the presence of GST-VCA and latrunculin B-bound actin
monomers, both double cysteine mutants produced a high706 Chemistry & Biology 20, 701–712, May 23, 2013 ª2013 Elseviermolecular weight band reactive to an anti-Arp3 antibody when
treated with bis(maleimido)ethane (BMOE), an 8 A˚ sulfhydryl
crosslinking reagent (Figure 5E). The crosslinked product also
reacted with an Arp2 antibody (Figure S3A) and did not form in
the single cysteine mutant controls, indicating that the crosslink
is between the engineered cysteines. Small molecule CK-869
does not inhibit the budding yeast Arp2/3 complex and did
not decrease formation of the Arp3-Arp2 crosslink, showing
there is a correlation between inhibition and the reduction in
crosslinking (Figure S3B). Therefore, both Arp-021 and Arp-
024 Arp2/3 complexes can be used to probe for the short pitch
conformation.
Actin Monomers Directly Contribute to Formation of the
Short Pitch Conformation
Binding of VCA alone causes conformational changes in Arp2/3
complex that have been investigated by fluorescence resonance
energy transfer (FRET) and two- and three-dimensional electron
microscopy reconstructions, but less is known about the influ-
ence of VCA bound to actin monomers (Boczkowska et al.,Ltd All rights reserved
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Mechanism of Arp2/3 Complex Inhibitors2008; Goley et al., 2004; Rodal et al., 2005; Xu et al., 2011).
Therefore, to better understand how the inhibitors influence the
conformation of the 2:2:1 assembly, we first used the cysteine
double mutants to test the relative contribution of actin mono-
mers and GST-VCA to formation of the short pitch conformation.
Unexpectedly, we found that a reaction containing GST-VCA but
not actin monomers had decreased crosslinking compared to a
reaction containing both actin monomers and GST-VCA (Fig-
ure 5F). These data demonstrate that actin monomers recruited
by VCA play an active role in favoring the short pitch conforma-
tional change. In some reactions, we observed crosslinking even
in the absence of activators, though it was always significantly
less than with VCA or actin monomers and VCA (Figure S3C).
This observation is consistent with the reported levels of consti-
tutive activity in budding yeast Arp2/3 complex (Wen andRuben-
stein, 2005) and with single-particle EM studies that show a
significant fraction of budding yeast Arp2/3 complex adopts a
closed (and presumably active) conformation in the absence of
NPFs (Rodal et al., 2005). Together, our results demonstrate
the short pitch conformation is sampled even without activators
but that GST-VCA and actin monomers cooperate to skew the
conformational equilibrium toward the short pitch conformation.
CK-869 and CK-666 Block Formation of the Short Pitch
Dimer
We next tested the effect of CK-666 on crosslinking. CK-666 at
200 mM eliminated the Arp2-Arp3 crosslink formed in the
absence of activating factors and reduced the amount of the
crosslinked band formed in the presence GST-VCA or GST-
VCA and actin (Figures 5G, 5H, and S3C). These data demon-
strate that CK-666 blocks formation of the short pitch confor-
mation, explaining how it inhibits nucleation by Arp2/3 complex.
Because crosslinking is blocked both in the presence or absence
of activators (Figure S3C), we conclude that the effect of CK-666
is not limited to the 2:2:1 assembly but that it also influences the
conformational equilibria of Arp2/3 alone or Arp2/3 complex
bound to GST-VCA.
The same crosslinking assay could not be used to directly test
if CK-869 affects formation of the short pitch dimer, because
CK-869 does not inhibit ScArp2/3 complex (Nolen et al., 2009).
However, the crosslinking data for CK-666 indicate that confor-
mational differences in the 2:2:1 assembly detected by AUC are
caused by a failure to adopt the short pitch conformation. CK-
869 had a similar influence on the complex as CK-666 in the
AUC experiments, suggesting CK-869 may also prevent forma-
tion of the short pitch dimer. We used the structure of the com-
plex with CK-869 and ATP bound to investigate this hypothesis.
Overlaying the structure onto Arp3 from the electron tomography
branch junction model showed that CK-869-induced changes in
Arp3 did not affect the short pitch interface. However, in this
model, the centers of mass of Arp2 and Arp3 are 46.8 A˚ apart
and share only 25 A˚2 of buried surface area (Rouiller et al.,
2008). In contrast, in the recently published8 A˚ cryo-EM struc-
ture of an actin filament, the centers of mass of two short pitch
actin monomers are separated by only 40.6 A˚ (Murakami et al.,
2010) and share 817 A˚2 of buried surface area. In this structure,
the b7/aC loop and the sensor loop contact the aE/aF loop from
the actin monomer in the short pitch position (Figure 5I). These
contacts require the b7/aC loop to bend downward toward theChemistry & Biology 20,barbed end relative to its position in actin monomer structures
(Murakami et al., 2010). When we superimposed Arp2 and CK-
869-bound Arp3 onto this structure, we found that the b7/aC
loop in Arp3 sterically clashes with the aE/aF loop in Arp2 (Fig-
ure 5I). Together with the AUC data, these models suggest that
the conformational changes in the sensor and b7/aC loop
caused by CK-869 may disrupt the short pitch interface of
Arp2 and Arp3. Therefore, our data are consistent with a model
in which CK-869 inhibits the Arp2/3 complex by destabilizing
the short pitch conformation.
DISCUSSION
CK-666 and CK-869 Use Distinct Structural
Mechanisms to Inhibit Arp2/3 Complex: Implications for
Inhibiting Protein-Protein Interactions
Here, we demonstrate that CK-666 inhibits Arp2/3 complex by
blocking formation of the short pitch Arp2-Arp3 dimer. The
structural basis for this conformational control by CK-666 is
evident in X-ray crystal structures, which showed that CK-666
stabilizes the splayed conformation by contacting residues
from Arp3 and Arp2 that are aligned only in the inactive state
(Baggett et al., 2012). Our data show that this stabilization is
sufficient to block formation of the short pitch dimer, thereby
inhibiting the complex. Binding of CK-666 requires only minor
side chain movements, so CK-666 inhibits by trapping a native
inactive conformation of the complex. Analogous trapping
mechanisms are commonly used by naturally occurring allo-
steric inhibitors, but there are relatively few examples of syn-
thetic compounds that exploit serendipitous allosteric sites for
conformational trapping (Hardy and Wells, 2004; Lee and Craik,
2009). These results raise the intriguing possibility that other
serendipitous sites on Arp2/3 complex might be exploited to
lock it into the short pitch conformation, providing a tool for
investigating both the mechanistic details of activation and
in vivo function of the complex.
Our data suggest that CK-869 also blocks formation of the
short pitch dimer. While CK-666 accomplishes this by stabilizing
the splayed conformation, CK-869 appears to destabilize the
short pitch interface of Arp2 and Arp3. Interestingly, it does not
bind to and directly blocks one side of this protein-protein inter-
face (PPI), the typical mode of action for PPI inhibitors (Wilson,
2009). Instead, it indirectly disrupts two key loops at the interface
by binding to a pocket near the PPI that normally anchors one of
the loops (Figure 6A). These results highlight the importance of
using computational methods that incorporate loop flexibility
into computational screening (B-Rao et al., 2009), even in cases
where surface loops are well-ordered and appear to be locked
into place in crystal structures, as observed for the sensor loop
in Arp3 structures without CK-869 (Nolen and Pollard, 2007). Un-
covering such serendipitous pockets near other important PPIs
could provide a general way to circumvent the problems inherent
in directly targeting the extensive and relatively flat surfaces
typical of PPIs (Wells and McClendon, 2007).
Implications for Understanding the Mechanism of
Branching Nucleation by Arp2/3 Complex
While actin filaments, actin monomers, ATP, and NPFs are all
required for activation, how biochemical states of the complex701–712, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 707
Figure 5. CK-666 Blocks Formation of the Short Pitch Arp2-Arp3 Dimer
(A) Structures of inactive (‘‘splayed,’’ 2P9K) and active (‘‘short pitch’’) (Rouiller et al., 2008) Arp2/3 complex showing relative orientation of Arp3 (orange) and Arp2
(red). Distance between engineered cysteine residues in mutants Arp-021 (green residues) and Arp-024 (blue atoms) in each conformation is indicated in the
table.
(B) Time courses of actin polymerization containing 3 mM 15% pyrene actin and 150 nM GST-VCA with a range of concentrations of wild-type or mutant Arp2/3
complex. Error bars are SDs from three separate experiments using either two (Arp-024, wild-type [WT]) or three (Arp-021) different preparations of Arp2/3
complex.
(C) Time courses of actin polymerization showing activation of mutant and wild-type complexes by 150 nM GST-VCA. Concentrations of complex were adjusted
to give similar maximum polymerization rates. (WT: 50 nM, Arp-021: 150 nM, Arp-024: 10 nM). The ‘‘no Arp’’ reaction contained 150 nM GST-VCA but no Arp2/3
complex.
(D) Plot of maximum polymerization rate versus concentration of CK-666. Reactions contained 150 nM GST-VCA plus inhibitor and were otherwise
identical to conditions in (C). IC50 values were as follows: wild-type, 20 ± 2 mM; Arp-021, 63 ± 23 mM; Arp-024, 110 ± 35 mM. Error bars represent SD from three
replicates.
(E) Both cysteines are required (double) for crosslinked product to form. Anti-Arp3 western blot of crosslinking reactions containing either double-cysteinemutant
Arp-021 or Arp-024 or the single-mutant version of each plus 10 mM GST-VCA and 10 mM Latrunculin-B actin.
(F) Anti-Arp3 western blots of crosslinking reactions containing 1 mM Arp2/3 complex, 100 mM BMOE, 10 mM GST-VCA, and 10 mM Latrunculin-B actin, as
indicated.
(G) Anti-Arp3 western blot of crosslinking reactions containing 10 mM GST-VCA, 10 mM Latrunculin-B actin, and CK-666 as indicated.
(H) Quantification of CK-666 inhibition of the short pitch crosslink. The fraction crosslinked was calculated by measuring the ratio of crosslinked to uncrosslinked
Arp3. Error bars represent standard error from three replicates.
(legend continued on next page)
Chemistry & Biology
Mechanism of Arp2/3 Complex Inhibitors
708 Chemistry & Biology 20, 701–712, May 23, 2013 ª2013 Elsevier Ltd All rights reserved
Figure 6. Cartoon Showing Proposed Struc-
tural Bases for Inhibition of Arp2/3 Complex
by CK-869 and CK-666
(A) In the inhibitor-free inactive state, the sensor
loop is closed over the CK-869 binding pocket and
the b7/aC loop of Arp3 is in the same conformation
observed in crystal structures of monomeric actin
(left panel). CK-869 binding locks the sensor loop
in an open conformation, and the b7/aC loop
moves toward subdomain 2 (middle panel). This
structural change destabilizes the Arp3-Arp2 short
pitch interface, because the b7/aC loop of Arp3
clashes with the aE/aF loop of Arp2 in the short
pitch position. In contrast, CK-666 stabilizes the
splayed conformation of Arp2/3 complex by
binding to the interface of Arp2 and Arp3 in the
inactive conformation (right panel).
(B) Simplified potential reaction pathway for
Arp2/3 complex activation. Steps affected by CK-
666 and CK-869 and highlighted and the hypoth-
esized conformational state of the complex at
each step are depicted. ATP binding causes cleft
closure in Arp3 (Nolen et al., 2004), and VCA
binding causes a compaction or closure of the
entire complex (Goley et al., 2004; Rodal et al.,
2005), which we depict here as a reordering and
closure of subdomains 1 and 2 of Arp2 from the
disordered (dotted line) state observed in inactive
Arp2/3 complex crystal structures. The switch
from the splayed to short pitch conformation in-
volves a25 A˚ movement of Arp2, which exposes
the barbed end of Arp3 for interaction with a VCA-
tethered actin monomer. This conformational
change is stimulated by VCA-recruited actin
monomers and blocked by both CK-666 and
CK-869.
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provide several important insights into the relationship between
activation and conformation.
First, binding of VCA alone is not sufficient to lock the complex
into the short pitch dimer conformation. Crosslinking assays
showed that NPF alone does not completely shift the equilibrium
to the short pitch state, since actin monomers were required to
maximize formation of crosslinked Arp2-Arp3 dimer. The extent
to which an NPF alone can promote the conformational change
may depend on multiple factors, including whether it engages
one or both sites and on the species of Arp2/3 complex. For
instance, our crosslinking data demonstrated that GST-VCA
increased the population of the short pitch state over no NPF
in the budding yeast complex. In contrast, the fluorescence
anisotropy binding data show binding of monomeric VCA to
the bovine complex is not influenced by the inhibitors, so VCA
cannot cause the short pitch dimer conformation to be signifi-
cantly populated, since this would result in thermodynamic(I) Model showing structural basis for inhibition of Arp2/3 complex by CK-869. Ste
structure superposed with an actin subunit (cyan) from a cryo-EM actin filament
carbon atoms. ‘‘S’’ marks the sensor loop and ‘‘7/C’’ marks the b7/aC loop in Arp3
relative to Arp3.
See also Figure S3.
Chemistry & Biology 20,microirreversibility. A precise understanding of the relationship
between NPF binding and the conformation of the complex will
be critical for understanding the fundamental mechanisms of
regulation of the complex.
Second, our crosslinking data demonstrate that actin mono-
mers stimulate formation of the short pitch Arp2-Arp3 dimer.
While previous data showed the V region of VCA is required
for activation of Arp2/3 complex by WASp/Scar family proteins
(Marchand et al., 2001), whether actin monomers are recruited
to the complex solely to bypass slow formation of an Arp2-
Arp3-actin hetero-oligomer or if they play a direct role in
activating the complex has been uncertain. Small-angle X-ray
scattering data showed that VCA recruits the first actin mono-
mer to the barbed end of Arp2 (Boczkowska et al., 2008). Steric
clash prevents the second actin from being delivered to the
barbed end of Arp3 when the complex is in the splayed confor-
mation (Figure 6B; Padrick et al., 2011). In contrast, the barbed
end of Arp3 is exposed in the short pitch conformation, leadingreo view diagram showing Arp3 (red) from the CK-869-bound Arp2/3 complex
structure (PDB ID code 3G37). CK-869 is shown as ball-and-sticks with purple
. ‘‘E/F’’ marks the aE/aF loop in the green actin subunit in the short pitch position
701–712, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 709
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cooperatively induce the short pitch conformation (Boczkowska
et al., 2008; Padrick et al., 2011). Our data strongly support this
model, and the crosslinking assay reported here will allow us to
directly test requirements for forming the short pitch dimer,
including recruitment of single versus two VCA actins to the
complex.
Third, our data demonstrate that binding of the complex to
actin filaments is not required to stimulate the short pitch confor-
mation. Actin filaments are required for Arp2/3 complex to
nucleate a filament (Achard et al., 2010; Higgs et al., 1999), so
our data suggest that formation of the short pitch dimer is not
sufficient for nucleation. One possibility is that the V region of
VCA blocks the barbed end of actin subunits in the 2:2:1 assem-
bly (Chereau et al., 2005; Padrick et al., 2011) and that binding of
the assembly to actin filaments is required for release of VCA
(Figure 6B). While this model is consistent with experiments
that suggest that VCA is released from branch junctions (Egile
et al., 2005; Martin et al., 2006), additional experiments will be
required to test this model.
One unexpected result of this work is that neither inhibitor
influenced binding of the Arp2/3 complex to the pointed end
of preformed actin filaments. Pointed end binding has been hy-
pothesized to shift the conformational equilibrium of the com-
plex to favor the short pitch dimer (Dayel and Mullins, 2004;
LeClaire et al., 2008). Our data suggest that the complex re-
mains splayed when bound to the pointed end. Because the
barbed end of Arp3 is blocked in the splayed conformation,
we speculate that the barbed end of Arp2 mediates interactions
with the pointed end and that this interaction is sufficient to shift
the nucleotide cleft of Arp2 into a hydrolysis-competent confor-
mation (Dayel and Mullins, 2004). We note that the failure of
Arp2/3 complex to adopt the short pitch conformation at the
pointed end is consistent with a recent high-resolution cryoelec-
tron microscopy structure, which shows that the terminal
pointed end actin subunit is titled and does not form the canon-
ical short pitch dimer with the penultimate actin subunit (Narita
et al., 2011).
Implications for Understanding Influence of Inhibitors
on In Vivo Branched Actin Networks
The molecular mechanism of each inhibitor has important impli-
cations for interpreting its influence on branched actin networks
in vivo. For instance, we have shown that the inhibitors do not
stimulate dissociation of preformed branches in vitro. Therefore,
the rate of disassembly of in vivo actin networks upon treat-
ment with the inhibitors reflects the rate of turnover of
Arp2/3-branched networks in the absence of inhibitors. Second,
we showed that the inhibitors block the nucleation activity of the
complex without altering its other biochemical activities. This
functional specificity has advantages over genetic ablation
methods, considering that knockout or knockdowns of Arp2/3
complex subunits result in destabilization and often complete
loss of the complex (Gournier et al., 2001). For example, neither
inhibitor significantly influenced NPF binding, indicating that the
inhibitors will not affect NPF-dependent localization of the
complex in vivo. Therefore, both inhibitors will be useful in inves-
tigating the recruitment of Arp2/3 complex to sites of actin
network initiation in the absence of branching nucleation.710 Chemistry & Biology 20, 701–712, May 23, 2013 ª2013 ElsevierSIGNIFICANCE
Here, we use biochemical and structural methods to dissect
the mechanism of Arp2/3 complex by small molecules CK-
666 and CK-869. This work provides several important
insights into the relationship between conformation and
activity of the Arp2/3 complex. We show that actin mono-
mers recruited by WASp-VCA stimulate the short pitch
conformation of the complex without requiring binding of
the complex to the sides of actin filaments, as previously
posited. Future mechanistic studies will be aimed at how
binding to actin filaments is coupled to activation so that
the complex creates only branched actin filament networks.
By demonstrating that the inhibitors do not influence the
interaction of the complexwith NPFs, ATP, or actin filaments
nor cause active disassembly of preformed branches, we
provide a mechanistic framework for understanding the in-
fluence of the inhibitors on actin networks in vivo. Finally,
by dissecting the structural/biochemical mechanisms of
two distinct inhibitors of the Arp2/3 complex, this work pro-
vides a conceptual basis for understanding how to inhibit
protein-protein interaction in macromolecular assemblies.
EXPERIMENTAL PROCEDURES
X-Ray Crystallography
Crystals of Bos taurus Arp2/3 complex were grown by hanging drop vapor
diffusion as previously described (Nolen et al., 2004). Crystals were transferred
to soaking solution containing 18% polyethylene glycol 8000; 50 mM 4-(2-hy-
droxyethyl)piperazine-1-ethanesulfonic acid (HEPES) pH 7.5; 100 mM potas-
sium thiocyanate; 20% glycerol; and either 0.5 mM CK-666, 0.5 mM
CK-869, or 0.5 mM CK-869 plus 2 mM ATP and 2 mM CaCl2 and soaked at
4C for 16 hr. Data were collected at beamline 5.0.1 or 4.2.2 at the Advanced
Light Source in Berkeley, CA. Phases were solved by molecular replacement
using the apo-Arp2/3 complex as a starting model (Protein Data Bank [PDB]
ID code 1K8K), and the structures were refined using crystallography and
nuclear magnetic resonance system (Bru¨nger et al., 1998) with inhibitor
parameter files generated using the prodrg server (Schu¨ttelkopf and van
Aalten, 2004). Structures were deposited in the PDB under ID codes 3UKU
and 3ULE.
Analytical Ultracentrifugation
Sedimentation velocity experiments were carried out in a Beckman XL-I
analytical ultracentrifuge. Samples were prepared with a final concentration
of 1 mM BtArp2/3 complex, 10 mM GST-VCA, and 10 mM actin (or 10 mM
70%Oregon green actin) with 20 mMLatrunculin B in AUCbuffer (5mMHEPES
pH 7.0, 50mMKCl, 1mMEGTA, 1mMMgCl2 with or without 150 mM inhibitor).
Latrunculin B was added to actin prior to mixing with the other protein compo-
nents. Actin and the other protein components were mixed 1:1 with a final
volume of 410 ml. Samples were loaded into a two-channel ultracentrifuge
cell, and a blank buffer consisting of the protein storage buffers, AUC buffer,
and latrunculin B mixed identically to the protein solutions was loaded into
the blank channel. For interference experiments, sapphire windows were
used, and for absorbance experiments, quartz windows were used. Cells
were loaded in an An-60Ti rotor and centrifuged at 50,000 rpm at 20C.
Data were analyzed using SEDFIT using a continuous c(s) with bimodal f/f0
(Schuck, 2000). Fits were considered satisfactory if the root mean square
deviation was less than 0.009 and the residuals were randomly distributed.
Dual Cysteine Crosslinking Assays
One micrometer Arp2/3 complex, 10 mM activator, 20 mM Latrunculin B, and
10 mM actin (as indicated) were incubated in buffer (10 mM imidazole
pH 7.0, 50 mM KCl, 10 mM EGTA, 10 mM MgCl2, 10 mM ATP, 10 mM
CaCl2). Latrunculin B was added to actin first in order to prevent spontaneousLtd All rights reserved
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Mechanism of Arp2/3 Complex Inhibitorspolymerization of the actin. One hundred micrometers BMOE was added at
room temperature to initiate the crosslinking reaction. After 10 s, 10mM dithio-
threitol was added to quench the reaction. Western blots were probed for Arp2
(antibody sc-11969) or Arp3 (antibody sc-11973). Additional experimental
details can be found in the Supplemental Information.
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